Confounding by Indication in Studies of Selective Serotonin Reuptake Inhibitors

키워드

참고문헌 (89)

1. Depression and other common mental disorders: global health estimates, "World Health Organization", World Health Organization, ~ (2017)
2. Yang H, "Type of residual symptom and risk of relapse during the continuation", maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine, 2010, pp.260, 145~150
3. Clevenger SS, "The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder", Ther Adv Psychopharmacol, 8, pp.49~58 (2018)
4. Malhi GS, "Depression", Lancet, 392, pp.2299~2312 (2018)
5. 왕승민, "Addressing the side effects of contemporary antidepressant drugs: a comprehensive review", 전남의대학술지, 54(2), pp.101~112 (2018), 의과학연구소[DOI]
6. Moret C, "Problems associated with long-term treatment with selective serotonin reuptake inhibitors", J Psychopharmacol, 23, pp.967~974 (2009)
7. Jakobsen JC, "Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis", BMC Psychiatry, 17, pp.58~ (2017)
8. Ferguson JM, "SSRI antidepressant medications: adverse effects and tolerability", Prim Care Companion J Clin Psychiatry, 3, pp.22~27 (2001)
9. EdinoffAN, "Selective serotonin reuptake inhibitors and adverse effects: a narrative review", Neurol Int, 13, pp.387~401 (2021)
10. Joseph KS, "Confounding by indication and related concepts", Curr Epidemiol Rep, 1, pp.1~8 (2014)
11. Miettinen OS, "The need for randomization in the study of intended effects", Stat Med, 2, pp.267~271 (1983)
12. Blais L, "Confounding by indication and channeling over time: the risks of beta 2-agonists", Am J Epidemiol, 144, pp.1161~1169 (1996)
13. Edwards JG, "Systematic review and guide to selection of selective serotonin reuptake inhibitors", Drugs, 57, pp.507~533 (1999)
14. Hall WD, "How have the SSRI antidepressants affected suicide risk?", Lancet, 367, pp.1959~1962 (2006)
15. Fergusson D, "Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials", BMJ, 330, pp.396~ (2005)
16. Barbui C, "Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies", CMAJ, 180, pp.291~297 (2009)
17. Gibbons RD, "Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets", Am J Psychiatry, 164, pp.1044~1049 (2007)
18. Tiihonen J, "Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort", Arch Gen Psychiatry, 63, pp.1358~1367 (2006)
19. Grimes DA, "Bias and causal associations in observational research", Lancet, 359, pp.248~252 (2002)
20. Didham RC, "Suicide and selfharm following prescription of SSRIs and other antidepressants: confounding by indication", Br J Clin Pharmacol, 60, pp.519~525 (2005)
21. Brännström J, "Association between antidepressant drug use and hip fracture in older people before and after treatment initiation", JAMA Psychiatry, 76, pp.172~179 (2019)
22. Walker AM, "Confounding by indication", Epidemiology, 7, pp.335~336 (1996)
23. Mussolino ME, "Depression and hip fracture risk: the NHANES I epidemiologic follow-up study", Public Health Rep, 120, pp.71~75 (2005)
24. Michelson D, "Bone mineral density in women with depression", N Engl J Med, 335, pp.1176~1181 (1996)
25. Coelho R, "Bone mineral density and depression: a community study in women", J Psychosom Res, 46, pp.29~35 (1999)
26. Amsterdam JD, "Adrenocortical responsiveness to the ACTH stimulation test in depressed patients and healthy volunteers", J Affect Disord, 11, pp.265~274 (1986)
27. Mezuk B, "Affective disorders, bone metabolism, and dsteoporosis", Clin Rev Bone Miner Metab, 6, pp.101~113 (2008)
28. Alghadir AH, "Physical activity and lifestyle effects on bone mineral density among young adults: sociodemographic and biochemical analysis", J Phys Ther Sci, 27, pp.2261~2270 (2015)
29. Glassman AH, "Smoking, smoking cessation, and major depression", JAMA, 264, pp.1546~1549 (1990)
30. Anda RF, "Depression and the dynamics of smoking. A national perspective", JAMA, 264, pp.1541~1545 (1990)
31. Simonsick EM, "Personal health habits and mental health in a national probability sample", Am J Prev Med, 7, pp.425~437 (1991)
32. Schoenborn CA, "Negative moods as correlates of smoking and heavier drinking: implications for health promotion", Adv Data, 236, pp.1~16 (1993)
33. Jing E, "Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review", Ment Health Clin, 6, pp.191~196 (2016)
34. Hendrick V, "Antidepressant medications, mood and male fertility", Psychoneuroendocrinology, 25, pp.37~51 (2000)
35. Casilla-Lennon MM, "The effect of antidepressants on fertility", Am J Obstet Gynecol, 215, pp.314.e1~314.e5 (2016)
36. Nillni YI, "Depression, anxiety, and psychotropic medication use and fecundability", Am J Obstet Gynecol, 215, pp.453.e1~453.e8 (2016)
37. Hernandez-Nieto C, "Embryo aneuploidy is not impacted by selective serotonin reuptake inhibitor exposure", Fertil Steril, 108, pp.973~979 (2017)
38. Andersen JT, "Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage", Obstet Gynecol, 124, pp.655~661 (2014)
39. Yland JJ, "A North American prospective study of depression, psychotropic medication use, and semen quality", Fertil Steril, 116, pp.833~842 (2021)
40. Yland JJ, "A prospective study of male depression, psychotropic medication use, and fecundability", Am J Mens Health, 16, pp.15579883221075520~ (2022)
41. Williams KE, "Mood disorders and fertility in women: a critical review of the literature and implications for future research", Hum Reprod Update, 13, pp.607~616 (2007)
42. Worly BL, "The effect of mental illness and psychotropic medication on gametes and fertility: a systematic review", J Clin Psychiatry, 76, pp.974~985 (2015)
43. Hall E, "Male fertility: psychiatric considerations", Fertil Steril, 97, pp.434~439 (2012)
44. Emokpae MA, "Effects of lifestyle factors on fertility: practical recommendations for modification", Reprod Fertil, 2, pp.R13~R26 (2021)
45. Yusuf S, "5-hydroxytryptamine and atrial fibrillation:how significant is this piece in the puzzle?", J Cardiovasc Electrophysiol, 14, pp.209~214 (2003)
46. Pino R, "Effect of 5-HT4 receptor stimulation on the pacemaker current I(f) in human isolated atrial myocytes", Cardiovasc Res, 40, pp.516~522 (1998)
47. Lanquillon S, "Cytokine production and treatment response in major depressive disorder", Neuropsychopharmacology, 22, pp.370~379 (2000)
48. Maes M, "The immunoregulatory effects of antidepressants", Hum Psychopharmacol, 16, pp.95~103 (2001)
49. Leonard BE, "The immune system, depression and the action of antidepressants", Prog Neuropsychopharmacol Biol Psychiatry, 25, pp.767~780 (2001)
50. Fenger-Grøn M, "Depression, antidepressants, and the risk of non-valvular atrial fibrillation: a nationwide Danish matched cohort study", Eur J Prev Cardiol, 26, pp.187~195 (2019)
51. Uchmanowicz I, "Assessment of frailty and occurrence of anxiety and depression in elderly patients with atrial fibrillation", Clin Interv Aging, 15, pp.1151~1161 (2020)
52. Rewiuk K, "Atrial fibrillation independently linked with depression in community-dwelling older population. Results from the nationwide PolSenior project", Exp Gerontol, 112, pp.88~91 (2018)
53. Pariante CM, "The HPA axis in major depression: classical theories and new developments", Trends Neurosci, 31, pp.464~468 (2008)
54. Dantzer R, "From inflammation to sickness and depression: when the immune system subjugates the brain", Nat Rev Neurosci, 9, pp.46~56 (2008)
55. Taler M, "Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs)on human T lymphocyte function and gene expression", Eur Neuropsychopharmacol, 17, pp.774~780 (2007)
56. Milaneschi Y, "Depression and obesity: evidence of shared biological mechanisms", Mol Psychiatry, 24, pp.18~33 (2019)
57. Nebhinani N, "Correlates of metabolic syndrome in patients with depression: a study from north-western India", Diabetes Metab Syndr, 14, pp.1997~2002 (2020)
58. Scalco AZ, "Hypertension and depression", Clinics (Sao Paulo), 60, pp.241~250 (2005)
59. Shi S, "Depression and risk of sudden cardiac death and arrhythmias: a meta-analysis", Psychosom Med, 79, pp.153~161 (2017)
60. Munk PS, "Symptoms of anxiety and depression after percutaneous coronary intervention are associated with decreased heart rate variability, impaired endothelial function and increased inflammation", Int J Cardiol, 158, pp.173~176 (2012)
61. Lip GY, "Atrial fibrillation", Lancet, 379, pp.648~661 (2012)
62. Alqdwah-Fattouh R, "Selective serotonin reuptake inhibitors and risk of noncardioembolic ischemic stroke: a nested case-control study", Stroke, 53, pp.1560~1569 (2022)
63. Hung CC, "The association of selective serotonin reuptake inhibitors use and stroke in geriatric population", Am J Geriatr Psychiatry, 21, pp.811~815 (2013)
64. Musselman DL, "The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment", Arch Gen Psychiatry, 55, pp.580~592 (1998)
65. Shimbo D, "Role of depression and inflammation in incident coronary heart disease events", Am J Cardiol, 96, pp.1016~1021 (2005)
66. Howren MB, "Associations of depression with Creactive protein, IL-1, and IL-6: a meta-analysis", Psychosom Med, 71, pp.171~186 (2009)
67. Kaptoge S, "C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant metaanalysis", Lancet, 375, pp.132~140 (2010)
68. Strine TW, "The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults", Gen Hosp Psychiatry, 30, pp.127~137 (2008)
69. Luppino FS, "Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies", Arch Gen Psychiatry, 67, pp.220~229 (2010)
70. Pan A, "Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review", JAMA, 306, pp.1241~1249 (2011)
71. Patten SB, "Major depression as a risk factor for high blood pressure:epidemiologic evidence from a national longitudinal study", Psychosom Med, 71, pp.273~279 (2009)
72. Pan A, "Bidirectional association between depression and type 2 diabetes mellitus in women", Arch Intern Med, 170, pp.1884~1891 (2010)
73. Sujan AC, "Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit", hyperactivity disorder in offspring, 2017, pp.317, 1553~1562
74. Brown HK, "Association between serotonergic antidepressant use during pregnancy and autism spectrum disorder in children", JAMA, 317, pp.1544~1552 (2017)
75. Anderson GM, "Platelet serotonin in newborns and infants: ontogeny, heritability, and effect of in utero exposure to selective serotonin reuptake inhibitors", Pediatr Res, 56, pp.418~422 (2004)
76. Cook EH Jr, "Free serotonin in plasma:autistic children and their first-degree relatives", Biol Psychiatry, 24, pp.488~491 (1988)
77. Gidaya NB, "In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder", J Autism Dev Disord, 44, pp.2558~2567 (2014)
78. Malm H, "Gestational exposure to selective serotonin reuptake inhibitors and offspring psychiatric disorders: a national registerbased study", J Am Acad Child Adolesc Psychiatry, 55, pp.359~366 (2016)
79. Viktorin A, "Autism risk following antidepressant medication during pregnancy", Psychol Med, 47, pp.2787~2796 (2017)
80. Sørensen MJ, "Antidepressant exposure in pregnancy and risk of autism spectrum disorders", Clin Epidemiol, 5, pp.449~459 (2013)
81. Hagberg KW, "Maternal depression and antidepressant use during pregnancy and the risk of autism spectrum disorder in offspring", Clin Epidemiol, 10, pp.1599~1612 (2018)
82. Gao SY, "Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births", BMC Med, 16, pp.205~ (2018)
83. Ogunyemi D, "The contribution of untreated and treated anxiety and depression to prenatal, intrapartum, and neonatal outcomes", AJP Rep, 8, pp.e146~e157 (2018)
84. Susser LC, "Selective serotonin reuptake inhibitors for depression in pregnancy", Am J Obstet Gynecol, 215, pp.722~730 (2016)
85. Jimenez-Solem E, "Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study", BMJ Open, 2, pp.e001148~ (2012)
86. Huybrechts KF, "Antidepressant use in pregnancy and the risk of cardiac defects", N Engl J Med, 370, pp.2397~2407 (2014)
87. Marcus SM, "Depression in childbearing women:when depression complicates pregnancy", Prim Care, 36, pp.151~165 (2009)
88. Santvana S, "Psychiatric disorders associated with pregnancy", J Obstet Gynecol India, 55, pp.218~227 (2005)
89. Newport DJ, "Maternal depression: a child’s first adverse life event", Semin Clin Neuropsychiatry, 7, pp.113~119 (2002)

관련 논문AI추천